📊 TRAW Key Takeaways
Is Traws Pharma, Inc. (TRAW) a Good Investment?
Traws Pharma faces imminent financial distress with negative stockholders' equity (-$629K), -$20.8M free cash flow burn, and -$17.9M operating losses. While revenue grew +1134%, the $2.8M base is insufficient to offset $18.2M operating cash outflows, leaving merely months of cash runway at current burn rates before insolvency.
Why Buy Traws Pharma, Inc. Stock? TRAW Key Strengths
- Explosive revenue growth of +1134.5% YoY demonstrates emerging market traction
- Positive cash position of $3.8M provides short-term operational runway
- Net income positive at $9.2M, indicating non-operating gains or favorable accounting treatment
TRAW Stock Risks: Traws Pharma, Inc. Investment Risks
- Negative stockholders' equity of -$629K indicates technical insolvency with liabilities exceeding assets
- Free cash flow of -$20.8M depletes cash reserves to zero within 2-3 months at current burn rate
- Operating cash flow of -$18.2M proves business model is not sustainable and entirely dependent on external capital
Key Metrics to Watch
- Cash runway and monthly burn rate (survival metric)
- Operating cash flow trend and path to breakeven
- Capital raising ability and terms (dilution risk if needed)
Traws Pharma, Inc. (TRAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
TRAW Profit Margin, ROE & Profitability Analysis
TRAW vs Healthcare Sector: How Traws Pharma, Inc. Compares
How Traws Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Traws Pharma, Inc. Stock Overvalued? TRAW Valuation Analysis 2026
Based on fundamental analysis, Traws Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Traws Pharma, Inc. Balance Sheet: TRAW Debt, Cash & Liquidity
TRAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Traws Pharma, Inc.'s revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $-22.57 indicates the company is currently unprofitable.
TRAW Revenue Growth, EPS Growth & YoY Performance
TRAW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $57.0K | -$4.7M | $-5.64 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Traws Pharma, Inc. Dividends, Buybacks & Capital Allocation
TRAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Traws Pharma, Inc. (CIK: 0001130598)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TRAW
What is the AI rating for TRAW?
Traws Pharma, Inc. (TRAW) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TRAW's key strengths?
Claude: Explosive revenue growth of +1134.5% YoY demonstrates emerging market traction. Positive cash position of $3.8M provides short-term operational runway.
What are the risks of investing in TRAW?
Claude: Negative stockholders' equity of -$629K indicates technical insolvency with liabilities exceeding assets. Free cash flow of -$20.8M depletes cash reserves to zero within 2-3 months at current burn rate.
What is TRAW's revenue and growth?
Traws Pharma, Inc. reported revenue of $2.8M.
Does TRAW pay dividends?
Traws Pharma, Inc. does not currently pay dividends.
Where can I find TRAW SEC filings?
Official SEC filings for Traws Pharma, Inc. (CIK: 0001130598) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TRAW's EPS?
Traws Pharma, Inc. has a diluted EPS of $0.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TRAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Traws Pharma, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TRAW stock overvalued or undervalued?
Valuation metrics for TRAW: ROE of N/A (sector avg: 15%), net margin of 328.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TRAW stock in 2026?
Our dual AI analysis gives Traws Pharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TRAW's free cash flow?
Traws Pharma, Inc.'s operating cash flow is $-18.2M, with capital expenditures of $2.6M. FCF margin is -744.4%.
How does TRAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 328.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.72 (avg: 2).